UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 27, 2020
|
SECOND SIGHT MEDICAL PRODUCTS, INC. |
|
|
(Exact Name of Registrant as Specified in Its Charter) |
|
|
California |
|
|
(State or Other Jurisdiction of Incorporation) |
|
|
001-36747 |
02-0692322 |
|
(Commission File Number) |
(IRS Employer Identification No.) |
|
12744 San Fernando Road, Suite 400 |
|
|
(Address of Principal Executive Offices) |
|
|
|
|
|
(818) 833-5000 |
|
|
(Registrant's Telephone Number, Including Area Code) |
|
|
(Former Name or Former Address, if Changed Since Last Report) |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ⎕
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ⎕
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Common Stock |
|
EYES |
|
Nasdaq |
|
|
Warrants |
|
EYESW |
|
Nasdaq |
|
_____________________________________________________________________________________________
ITEM 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 27, 2020, Second Sight Medical Products, Inc. (the “Company”) received written notice from William J. Link, a member of the Board of Directors of the Company (“Board”) and member of the Audit Committee, notifying the Company that he was resigning as a director effective May 31, 2020. In connection with Mr. Link’s resignation, there were no disagreements with the Company, known to an executive officer of the Company, on any matter relating to the Company’s operations, policies or practices.
Dr. Link’s resignation reduces the size of the Board to four members until a replacement for him is appointed. As a result, the Company has one remaining independent director. The Company previously reported on its Form 8-K filed April 21, 2020 that it no longer complies with Nasdaq’s independent director and audit committee requirements set forth in Nasdaq Listing Rule 5605. As set forth in that Form 8-K, Nasdaq has provided the Company with a compliance period in which to regain compliance with the listing requirement, however the Company cannot assure that it will be able to regain compliance within the period provided by Nasdaq.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 27, 2020
SECOND SIGHT MEDICAL PRODUCTS, INC.
|
/s/ John T. Blake |
By: John T. Blake